Danaher (DHR) Offering Possible 6.95% Return Over the Next 3 Calendar Days

Danaher's most recent trend suggests a bullish bias. One trading opportunity on Danaher is a Bull Put Spread using a strike $155.00 short put and a strike $145.00 long put offers a potential 6.95% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $155.00 by expiration. The full premium credit of $0.65 would be kept by the premium seller. The risk of $9.35 would be incurred if the stock dropped below the $145.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Danaher is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Danaher is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Danaher

It’s Time to Be Cautious With General Electric Stock
Thu, 09 Jan 2020 19:23:34 +0000
As with many other stocks in 2019, General Electric (NYSE:GE) ended with a nice bullish move. Starting in early October, shares of GE stock went from $8.28 to around $12 per share. This put the year-long return for 2019 at about 53%, which exceeded the gain on the S&P 500.Source: testing / Shutterstock.com This performance, though, is more than just about general optimism in the overall markets. CEO Larry Culp has done a standout job at the helm since coming on board in October 2018.Although, this should not be a surprise. When he was the CEO of Danaher (NYSE:DHR) — from 2000 to 2014 — there was a five-fold jump in both the revenues and market cap.InvestorPlace – Stock Market News, Stock Advice & Trading TipsHe showed that he can effectively manage the strategic vision, as well as the nuanced details of a complex organization. He also demonstrated a great ability to apply process methodologies, like lean manufacturing — which strives for continuous improvement. This approach was initially innovated at Toyota (NYSE:TM). * 8 of the Strangest Stocks Worth Your Time When Culp became CEO of GE, the situation was dire. The company had gone through two CEOs, the shares were delisted from the Dow, the dividend was slashed and the losses were piling up. From 2016 to 2018, the General Electric stock went from $32 to under $7.However, Culp put together a smart playbook to right the ship. Of course, a key part of this was an aggressive focus on reducing the bloated cost structure. He also was swift in unloading assets, like the biotech business and Baker Hughes (NYSE:BKR).Yet, this was mostly about the low-hanging fruit. Going forward, it will likely be more difficult to find ways to improve the organization. Many Problems RemainOne of the biggest issues for GE stock is the GE engine segment, which accounts for a hefty 60% of the industrial profits. The problem, of course, is Boeing's (NYSE:BA) 737 MAX, which has been sidelined due to two traffic airline crashes. It is still far from clear when production and deliveries will resume. But in the meantime, GE is feeling the impact, with a quarterly loss of $400 million in cash flows. This is likely to put lots of pressure on the company given the enormous debt load of $93.2 billion.Furthermore, the other company segments are also lagging. For example, even though the Power business has shown improvement, revenues were still off by 14% in the latest quarter. What's more, the Healthcare Systems unit has been mostly lackluster, with a meager 5% increase on the top line. There has continued to be weakness in China and the Middle East.Then there is GE Capital, which is suffering from the liabilities of its long-term care business. In the quarter, there was a loss of $645 million. Bottom Line on the GE Stock PriceFor the most part, Culp has stabilized operations, which is definitely crucial. Not long ago, there were serious concerns about the viability of GE; The situation had gotten that bad.But despite all this, it does look like that much of the good news has already been factored into GE stock. Consider that the forward price-to-earnings ratio is 18x, which is rich for a company that still has a host of problems. By comparison, Honeywell (NYSE:HON) trades at 20X and United Technologies (NYSE:UTX) is at 18X. No doubt, both of these companies are on much more solid footing.So, at least in the near-term, it's probably best to be cautious with GE stock.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 of the Strangest Stocks Worth Your Time * 7 Stocks to Buy That Trump's Tax Cut Truly Rewarded * 5 Stocks That Could Double in 2020 The post Ita€™s Time to Be Cautious With General Electric Stock appeared first on InvestorPlace.

Danaher To Present At J.P. Morgan Healthcare Conference
Thu, 09 Jan 2020 11:00:00 +0000
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2020 at 8:00 a.m. PT. The audio will be simultaneously webcast on and the presentation will be archived on www.danaher.com.

5 Companies Hit 52-Week Highs
Wed, 08 Jan 2020 15:59:15 +0000
As of late, these companies have reached annual price milestones Continue reading…

Danaher Schedules Fourth Quarter 2019 Earnings Conference Call
Tue, 07 Jan 2020 21:15:00 +0000
Danaher Corporation (NYSE: DHR) announced today that it will webcast its quarterly earnings conference call for the fourth quarter 2019 on Thursday, January 30, 2020 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Top Health Care Stocks for January 2020
Tue, 07 Jan 2020 16:00:22 +0000
These are the health care stocks with the best value, fastest growth, and most momentum for January.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.